These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 26551150

  • 1. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
    Kikushige Y, Miyamoto T.
    Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
    [Abstract] [Full Text] [Related]

  • 2. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
    Kikushige Y, Akashi K.
    Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
    [Abstract] [Full Text] [Related]

  • 3. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
    Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y, Akashi K.
    Cell Stem Cell; 2010 Dec 03; 7(6):708-17. PubMed ID: 21112565
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.
    Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S, Niiro H, Yurino A, Miyawaki K, Takenaka K, Iwasaki H, Akashi K.
    Cell Stem Cell; 2015 Sep 03; 17(3):341-52. PubMed ID: 26279267
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    Nakao K, Minato N, Uemoto S, Akashi K.
    ; 2015 Sep 03. PubMed ID: 29787181
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hypothesis: Tim-3/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages.
    Gao L, Yu S, Zhang X.
    Cell Biochem Biophys; 2014 Sep 03; 70(1):273-7. PubMed ID: 24639110
    [Abstract] [Full Text] [Related]

  • 14. [Molecular targeted therapy for leukemic stem cells].
    Kikushige Y.
    Nihon Rinsho; 2015 May 03; 73(5):811-5. PubMed ID: 25985636
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [New approaches to target leukemia stem cells].
    Takenaka K, Akashi K.
    Nihon Rinsho; 2014 Jun 03; 72(6):1018-25. PubMed ID: 25016798
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A, Bialopiotrowicz E, Krzymieniewska B, Wozniak J, Stojak M, Cybulska M, Kaniuga E, Mikula M, Jablonska E, Gorniak P, Noyszewska-Kania M, Szydlowski M, Piechna K, Piwocka K, Bugajski L, Lech-Maranda E, Barankiewicz J, Kolkowska-Lesniak A, Patkowska E, Glodkowska-Mrowka E, Baran N, Juszczynski P.
    Cell Death Dis; 2020 Nov 06; 11(11):956. PubMed ID: 33159047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.